Despite a promising approach for certain leukemia patients, the path to market appears to be in question.
| less than a minute read
This CD22 Approach Highlights the Importance of Experimental Medicine - and Collaboration
Get in touch
Get in touch
The therapy was developed at the National Cancer Institute, and Dr. Mackall said researchers did not know if a company would try to bring it to market.
Get in touch
Get in touch
Latest Insights
/Passle/58a5cb8db00e8110e83aa395/MediaLibrary/Images/2026-09-22-15-19-50-498-6ab29c96af556e9074387689.jpg)
/Passle/58a5cb8db00e8110e83aa395/MediaLibrary/Images/2026-09-15-18-23-35-620-6aa98d270810fd5205abd644.png)
/Passle/58a5cb8db00e8110e83aa395/MediaLibrary/Images/2026-09-01-21-26-53-841-6a97431d406533fea8d4615c.gif)